Research Grants 12/21191-6 - Neoplasias em animal, Cães - BV FAPESP
Advanced search
Start date
Betweenand

Mesenchymal stem cells (MSCs) and morphogenetic protein (rhBMP-2) associated to chemotherapy: a new perspective for a canine osteosarcoma therapy

Grant number: 12/21191-6
Support Opportunities:Regular Research Grants
Start date: April 01, 2013
End date: March 31, 2015
Field of knowledge:Agronomical Sciences - Veterinary Medicine - Animal Reproduction
Principal Investigator:Rose Eli Grassi Rici
Grantee:Rose Eli Grassi Rici
Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated researchers:Durvanei Augusto Maria

Abstract

Osteosarcomas, classified as mesenchymal tumors, described as a malignant bone tumor accounting for 80% of tumors, very common in dogs, cats and humans. Our results "in vitro" suggests that treatment of MSCs with fetal canine bone marrow (MSC) with bone morphogenetic protein (rhBMP-2) was able to induce the osteogenic potential and p53-mediated tumor suppression. "In vivo" we observe that there are no toxicity mechanisms that alter mitochondrial metabolism. Apoptosis found in the different treatments are due to the effects of immunomodulators and rhBMP2 MSC, which represents a potential antitumor and inhibiting the formation of metastases. The proposed project aims to study a new experiment on the effect of tumor suppression using MSC, rhBMP2 association and Carboplatin (chemotherapy) for the treatment of canine osteosarcoma. The cells of canine osteosarcoma (OST) will be deployed in mice BalbC nude / nude after its implementation will be treated with MSC, rhBMP-2 and Carboplatin. The analysis of the samples after treatment will be by flow cytometry using markers that express tumor suppressor, elucidating the mechanism of action of rhBMP-2 MSC and Carboplatin in OST. Cell therapy may be a novel therapeutic strategy and the project is of great relevance, since results obtained "in vivo" and "in vitro" promising. A new treatment strategy in clinical validate therapy for canine osteosarcoma. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
RICI, R. E. G.; WILL, S. E. A. L.; LUNA, A. C. L.; MELO, L. F.; SANTOS, A. C.; RODRIGUES, R. F.; LEANDRO, R. M.; MARIA, D. A.. Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model. VETERINARY AND COMPARATIVE ONCOLOGY, v. 16, n. 4, p. 478-488, . (12/21191-6)